Additionally, the TNBC phenotype is the most observed molecular subtype in patients with BRCA1 mutation and it is well documented that breast cancer patients with BRCA1 mutation are significantly associated with worse overall survival than patients with a non-mutated BRCA1 allele (pooled HR = 1.69 (95% CI 1.35 to 2.12, p < 0.001; I2 = 59.1%) (Zhu et al., 2016). The gene discussed is BRCA1; the disease is breast cancer.